The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) pandemic has led to rapid vaccine development and emergency use (EU) rollout. Six vaccines, including two using novel mRNA technology, are EU-listed by the World Health Organisation, and promising published trial data are available for nine more. While efficacy is good, there are various barriers to their global use. Long-term safety and immunogenicity data are being collected along the way.
Keyphrases
- respiratory syndrome coronavirus
- coronavirus disease
- sars cov
- public health
- electronic health record
- healthcare
- big data
- emergency department
- clinical trial
- study protocol
- phase iii
- mental health
- phase ii
- health information
- deep learning
- quantum dots
- open label
- sensitive detection
- loop mediated isothermal amplification
- meta analyses
- health promotion